MedMira Receives Order of Half a Million HIV tests from Vitest

Company Now a Registered Supplier for the United Nations Population Fund (UNPFA)

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced that its strategic sales and marketing partner, Vitest AG (Vitest), has placed an order for 510,000 rapid HIV tests to fulfill the initial sales in Africa. Vitest has been working in the region for the past several months, developing market opportunities for MedMira's rapid HIV tests.

Building on the Company's increasing focus on Africa and other developing regions along with the need to further develop relationships with international organizations, MedMira has also received notification from the United Nation Global Marketplace (UNGM) that its application to become a registered supplier for the United Nation Population Fund (UNPFA) has been accepted.

MedMira and its strategic partner Vitest are now able to participate in the many UNPFA procurement opportunities.

"Our strategic partnership plan has reached its first major milestone. The combination of manufacturing services and sales partnerships has empowered our ability to increase our revenue expectation for the coming year," said Hermes Chan, CEO, MedMira Inc. "We're also very excited to become a registered supplier for the UNPFA and we are pursuing additional registrations from various organizations within the United Nation Global Marketplace in order to broaden our opportunities within the international development sector."

Chan continued, "Over the course of the past week we had the opportunity to work in person with Vitest, when their team visited our Halifax headquarters. Our teams collaborated to further strengthen our strategic market development plan and increase our focus on fulfilling the demand for quality diagnostics in Africa and other developing regions."

This order is a direct result of Vitest's focused efforts to establish the MedMira product as a quality alternative to the current status quo in Africa. Vitest and MedMira's increasingly efficient partnership has led to very positive progress to date.

"This order in excess of half a million tests will further enhance the demand for MedMira's quality tests around the world. The recent public acknowledgement of the HIV epidemic in South Africa by President Jacob Zuma, is a huge milestone in the fight against HIV within this country, and the timely commitment of US$2.7 billion pledged by President Obama to help fight HIV infection in Kenya, have reinforced the public need for quality rapid tests. Our market development in Africa is progressing rapidly and we will look to further expand our presence and the awareness of our products with governments, international development agencies, and other NGOs working in the region," said Nicholas Dellaportas, Director of International Business Development and Sales, Vitest AG. "To date end-user feedback on the MedMira product has been very encouraging and we believe that the African market has matured to a point where quality, speed, and ease-of-use, all key features of the MedMira test, are of the utmost importance and will be a huge advantage to all health care providers within the continent."

Vitest AG

Vitest AG is a privately held company based in Wollerau, Switzerland (www.vitest.ch) with a corporate subsidiary in Germany (Vitest GmbH) and South Africa (Vitest Southern Africa Ply). Vitest is the manufacturer/distributor of medical rapid tests and known well for their high quality products. The company provides doctors offices, clinics, private companies, NGOs and government institutions with innovative rapid tests. With the introduction of the MedMira product range to the African and European markets, Vitest takes the lead in the latest disease prevention movement to reduce the number of new infections in the developed and the developing world, by making better diagnostics more widely available. For more information about Vitest, please contact Nicholas Dellaportas (This email address is being protected from spambots. You need JavaScript enabled to view it.), Director of International Business Development and Sales, Vitest AG, UK - 33 Thames Point, The Boulevard, Imperial Wharf, London, SW6 2 SX, +44 7711 826550, Fax. +4420 7371 5110.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E

SOURCE: MEDMIRA INC.

Andrea Young, MedMira, (902) 450-1588, This email address is being protected from spambots. You need JavaScript enabled to view it.